ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced the launching of the Veltmeyer Institute for Advanced Biologics (www.veltmeyerinstitute.org). The organization is focused on providing patients access to JadiCell adult stem cells in the field of brain and lung conditions under the Right to Try Law in applicable cases.
The Veltmeyer Institute is believed to be the only organization providing allogeneic stem cells that have been cleared by the FDA for clinical trials. The Veltmeyer Institute leverages the experience of Dr. James Veltmeyer who has treated over 100 patients under the Right to Try Law in collaboration with Therapeutic Solutions International and other Biotechnology Companies.
“I have always been a strong believer that patients should not have to leave the United States to receive access to the most cutting-edge technologies,” said Dr. James Veltmeyer, who is Chief Medical Officer of Therapeutic Solutions International and Founder of the Institute that bears his name. “I am proud to have assembled a first-class team of medical and marketing professionals to develop the Veltmeyer Institute as the premium destination for patients with incurable conditions who seek access to regenerative medicine approaches as well as immunotherapy for end stage cancer.”
“I speak for the whole TSOI Family that Dr. Veltmeyer is by far the kindest, most knowledgeable, and most effective medical doctor that we have worked quietly with all these years,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “I am proud that we have been successful in creating this Institute which will provide a base for providing patient rapid access to stem cells and other treatments in a safe and legal way in the United States of America.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
